Anixa Biosciences (ANIX) Change in Receivables (2010 - 2025)
Anixa Biosciences' (ANIX) quarterly Change in Receivables came in at -$173000.0 in Q1 2025, down 242.98% YoY from $121000.0 in Q1 2024, and up 27.0% on a QoQ basis from -$237000.0 in Q4 2024.
Anixa Biosciences (ANIX) Change in Receivables (2010 - 2025) Analysis & Trends
Anixa Biosciences (ANIX) has 12 years of Change in Receivables data on file, last reported at -$173000.0 in Q1 2025.
- Quarterly Change in Receivables fell 242.98% year-over-year to -$173000.0 in Q1 2025, while the trailing twelve-month figure through Oct 2025 was -$173000.0 (down 78.35% YoY) and the FY2025 annual result came in at -$173000.0, down 78.35% from the prior year.
- Change in Receivables climbed to -$173000.0 in Q1 2025, from -$237000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $192000.0 in Q3 2024 to a low of -$237000.0 in Q4 2024.
- A 3-year average of -$5111.1 and a median of $79000.0 in 2023 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 143.04% in 2024, down 270.31% in 2024.
- Tracing ANIX's Change in Receivables over 3 years: stood at -$64000.0 in 2023, then slumped by 270.31% to -$237000.0 in 2024, then increased by 27.0% to -$173000.0 in 2025.
- The last three Change in Receivables figures came in at -$173000.0 (Q1 2025), -$237000.0 (Q4 2024), and $192000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2025 | -173,000.00 |
| Jan 31, 2025 | -173,000.00 |
| Oct 31, 2024 | -237,000.00 |
| Oct 31, 2024 | -237,000.00 |
| Jul 31, 2024 | 192,000.00 |
| Jul 31, 2024 | 192,000.00 |
| Apr 30, 2024 | -173,000.00 |
| Apr 30, 2024 | -173,000.00 |
| Jan 31, 2024 | 121,000.00 |
| Jan 31, 2024 | 121,000.00 |
| Oct 31, 2023 | -64,000.00 |
| Oct 31, 2023 | -64,000.00 |
| Jul 31, 2023 | 79,000.00 |
| Jul 31, 2023 | 79,000.00 |
| Apr 30, 2023 | 109,000.00 |
| Apr 30, 2023 | 109,000.00 |
| Jan 31, 2023 | 100,000.00 |
| Jan 31, 2023 | 100,000.00 |
| Oct 31, 2020 | -3,719.00 |
| Oct 31, 2020 | -3,719.00 |